|Grant Number:||3R01CA075903-14S1 Interpret this number|
|Primary Investigator:||Wood, Charles|
|Organization:||University Of Nebraska Lincoln|
|Project Title:||Kaposi's Sarcoma and Human Herpesvirus in Africa|
DESCRIPTION (provided by applicant): Incidence of Kaposi's sarcoma (KS) - a devastating malignancy closely associated with HIV/AIDS - is still very wide-spread in sub-Saharan African countries such as Zambia, where anti-retroviral therapy (ARV) has only recently become available. Human herpesvirus-8 (HHV-8) or Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent associated with KS. Our laboratory is widely recognized for its study of the transmission of HIV and HHV-8 and the establishment of a large mother-infant cohort in Zambia to study those two viruses. We were the first to establish that HHV-8 can be transmitted perinatally and together with HIV contribute to the increase of Kaposi's sarcoma in children in Africa. More recently, in collaboration with CDC- GAP Zambia, we determined the early childhood infection rate of HHV-8. As such, we are ideally positioned to lead the proposed study, the first of its magnitude in the African setting. We have found perinatal transmission can occur in utero, but most HHV-8 infections occur during early childhood via horizontal transmission, with HHV-8 seroconversion occurring even in instances where the child's mother or entire household is HHV-8 negative. Moreover, HIV-1 is a major risk factor for HHV-8 infection, and we found HIV-1 infected children have a five-fold higher risk for infection by HHV-8 as compared to uninfected children, most likely due to immune suppression as a result of HIV-1 infection. It is possible that restoration of the immune response via ARV will reduce HHV-8 infection of HIV-1 positive children and enhance the immune response against HHV-8 in infected individuals. Unfortunately, the impact of ARV on HHV-8 transmission and on HHV-8 disease pathogenesis is unknown. We hypothesize that the treatment of HIV-1 infected children by ARV will substantially lower their risk of being infected by HHV-8 and reduce the risk of disease progression toward developing KS in infected children by enhancing their anti-HHV-8 immune response and reducing viral reactivation. The overall objective of the proposed study is to make use of our established study infrastructure to determine the impact of ARV treatment on HHV-8 transmission, on anti-HHV-8 immune response, and on viral reactivation. We propose to utilize relevant participants in our existing cohort and to recruit additional subjects for our proposed study, as appropriate. To test the validity of our hypothesis, we are proposing two aims. The first is to determine whether ARV treatment of HIV-1 infected children will reduce their susceptibility to HHV-8 infection. The second is to determine whether ARV treatment of HIV-1 and HHV-8 dually infected children will enhance their immune response against HHV-8 and reduce viral reactivation. We anticipate that the data generated through the proposed effort will be useful in the development of future intervention strategies to prevent HHV-8 transmission.
Seroprevalence of human herpesvirus 8 and hepatitis C virus among drug users in Shanghai, China.
Authors: Zhang T, Liu Y, Zhang Y, Wang J, Minhas V, Wood C, He N
Source: Viruses, 2014 Jun 23;6(6), p. 2519-30.
EPub date: 2014 Jun 23.
Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection.
Authors: Wang LX, Kang G, Kumar P, Lu W, Li Y, Zhou Y, Li Q, Wood C
Source: Proc Natl Acad Sci U S A, 2014 Feb 25;111(8), p. 3146-51.
EPub date: 2014 Feb 10.
Kaposi`s sarcoma associated herpesvirus infection among female sex workers and general population women in Shanghai, China: a cross-sectional study.
Authors: Zhang T, Yang Y, Yu F, Zhao Y, Lin F, Minhas V, Wood C, He N
Source: BMC Infect Dis, 2014 Feb 5;14, p. 58.
EPub date: 2014 Feb 5.
Risk factors for early childhood infection of human herpesvirus-8 in Zambian children: the role of early childhood feeding practices.
Authors: Crabtree KL, Wojcicki JM, Minhas V, Smith DR, Kankasa C, Mitchell CD, Wood C
Source: Cancer Epidemiol Biomarkers Prev, 2014 Feb;23(2), p. 300-8.
EPub date: 2013 Dec 2.
Inactivation and viral load quantitation of human immunodeficiency virus in blood collected into Cyto-Chex(®) BCT blood collection device.
Authors: Kwon E, Minhas V, Phiri T, Wood C, Swindells S, Hunsley BA, Fernando MR
Source: J Virol Methods, 2014 Feb;196, p. 50-5.
EPub date: 2013 Oct 30.
Kaposi's sarcoma-associated herpesvirus transactivator Rta induces cell cycle arrest in G0/G1 phase by stabilizing and promoting nuclear localization of p27kip.
Authors: Kumar P, Wood C
Source: J Virol, 2013 Dec;87(24), p. 13226-38.
EPub date: 2013 Sep 25.
Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.
Authors: Guo H, Liu C, Liu B, Wood C, Kong X
Source: J Clin Virol, 2013 Sep;58(1), p. 233-9.
EPub date: 2013 Jun 25.
Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.
Authors: Gonzalez S, Tully DC, Gondwe C, Wood C
Source: Curr HIV Res, 2013 Jan;11(1), p. 43-9.
Prevalence and correlates of Kaposi's sarcoma-associated herpesvirus infection in a sample of men who have sex with men in Eastern China.
Authors: Zhang T, Lin H, Minhas V, Zhu W, Wood C, He N
Source: Epidemiol Infect, 2013 Sep;141(9), p. 1823-30.
EPub date: 2012 Oct 31.
Early childhood infection of Kaposi's sarcoma-associated herpesvirus in Zambian households: a molecular analysis.
Authors: Olp LN, Shea DM, White MK, Gondwe C, Kankasa C, Wood C
Source: Int J Cancer, 2013 Mar 1;132(5), p. 1182-90.
EPub date: 2012 Aug 20.
Dynamics of envelope evolution in clade C SHIV-infected pig-tailed macaques during disease progression analyzed by ultra-deep pyrosequencing.
Authors: Tso FY, Tully DC, Gonzalez S, Quince C, Ho O, Polacino P, Ruprecht RM, Hu SL, Wood C
Source: PLoS One, 2012;7(3), p. e32827.
EPub date: 2012 Mar 12.
Human herpesvirus 8 seroprevalence, China.
Authors: Zhang T, Shao X, Chen Y, Zhang T, Minhas V, Wood C, He N
Source: Emerg Infect Dis, 2012 Jan;18(1), p. 150-2.
Human papillomavirus 16 variants from Zambian women with normal pap smears.
Authors: Lei YJ, Makhaola K, Pittayakhajonwut D, Wood C, Angeletti PC
Source: J Med Virol, 2011 Jul;83(7), p. 1230-7.
The Zambia Children's KS-HHV8 Study: rationale, study design, and study methods.
Authors: Minhas V, Crabtree KL, Chao A, Wojcicki JM, Sifuniso AM, Nkonde C, Kankasa C, Mitchell CD, Wood C
Source: Am J Epidemiol, 2011 May 1;173(9), p. 1085-92.
EPub date: 2011 Mar 28.
HIV-1 clade B and C isolates exhibit differential replication: relevance to macrophage-mediated neurotoxicity.
Authors: Constantino AA, Huang Y, Zhang H, Wood C, Zheng JC
Source: Neurotox Res, 2011 Oct;20(3), p. 277-88.
EPub date: 2011 Feb 19.
Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.
Authors: Iordanskiy S, Waltke M, Feng Y, Wood C
Source: Retrovirology, 2010 Oct 12;7, p. 85.
EPub date: 2010 Oct 12.
Molecular determinants of HIV-1 subtype C coreceptor transition from R5 to R5X4.
Authors: Zhang H, Tully DC, Zhang T, Moriyama H, Thompson J, Wood C
Source: Virology, 2010 Nov 10;407(1), p. 68-79.
EPub date: 2010 Aug 24.
Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia.
Authors: Gonzalez S, Gondwe C, Tully DC, Minhas V, Shea D, Kankasa C, M'soka T, Wood C
Source: AIDS Res Hum Retroviruses, 2010 Jul;26(7), p. 795-803.
Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China.
Authors: Zhang T, He N, Ding Y, Crabtree K, Minhas V, Wood C
Source: Clin Microbiol Infect, 2011 Mar;17(3), p. 395-401.
Chronology and evolution of the HIV-1 subtype C epidemic in Ethiopia.
Authors: Tully DC, Wood C
Source: AIDS, 2010 Jun 19;24(10), p. 1577-82.
Enhancement of autophagy during lytic replication by the Kaposi's sarcoma-associated herpesvirus replication and transcription activator.
Authors: Wen HJ, Yang Z, Zhou Y, Wood C
Source: J Virol, 2010 Aug;84(15), p. 7448-58.
EPub date: 2010 May 19.